You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia

  • Technology appraisal guidance
  • Reference number: TA193
  • Published:  28 July 2010
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Appeal: UK Chronic Lymphocytic Leukaemia (CLL) Forum

  • Appeal received

  • Initial scrutiny letter

  • Response to initial scrutiny letter

  • Final scrutiny letter

  • Appraisal committee chair's response

  • Response to appraisal committee


This page was last updated: 21 May 2010

Back to top